Preclinical optimization of safety and duration of cold plasma against cancer

The goal of this research is to reduce the risks of recurrence and the treatment side effects for breast cancer patients by combining a new cold plasma technology to the standard of care (surgery and radiotherapy). Cold plasma generates locally specific reactive oxygen species that can kill cancer cells. It could be delivered directly in the tumor bed after the removal of the tumor, to kill remaining cancer cells and therefore improve local control. This project has the potential to enable a Canadian technology, which was invented at McGill University, to become a new adjuvant therapy, alone or in combination with radiotherapy, to help reduce the risks of breast cancer recurrence. This project will perform the last preclinical tests required to provide evidence that this technology has the potential to become a clinically relevant tool.

Faculty Supervisor:

Philip Wong

Student:

Partner:

Nexplasmagen

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Université de Montréal

Program: